These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 24121277)

  • 61. HMGA2 as a functional antagonist of PARP1 inhibitors in tumor cells.
    Hombach-Klonisch S; Kalantari F; Medapati MR; Natarajan S; Krishnan SN; Kumar-Kanojia A; Thanasupawat T; Begum F; Xu FY; Hatch GM; Los M; Klonisch T
    Mol Oncol; 2019 Feb; 13(2):153-170. PubMed ID: 30289618
    [TBL] [Abstract][Full Text] [Related]  

  • 62. PARP inhibitors: new partners in the therapy of cancer and inflammatory diseases.
    Peralta-Leal A; Rodríguez-Vargas JM; Aguilar-Quesada R; Rodríguez MI; Linares JL; de Almodóvar MR; Oliver FJ
    Free Radic Biol Med; 2009 Jul; 47(1):13-26. PubMed ID: 19362586
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Poly(ADP-ribose) polymerase-1: what have we learned from the deficient mouse model?
    Shall S; de Murcia G
    Mutat Res; 2000 Jun; 460(1):1-15. PubMed ID: 10856830
    [TBL] [Abstract][Full Text] [Related]  

  • 64. p21CDKN1A Regulates the Binding of Poly(ADP-Ribose) Polymerase-1 to DNA Repair Intermediates.
    Dutto I; Sukhanova M; Tillhon M; Cazzalini O; Stivala LA; Scovassi AI; Lavrik O; Prosperi E
    PLoS One; 2016; 11(1):e0146031. PubMed ID: 26730949
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Resistance to DNA-damaging treatment in non-small cell lung cancer tumor-initiating cells involves reduced DNA-PK/ATM activation and diminished cell cycle arrest.
    Lundholm L; Hååg P; Zong D; Juntti T; Mörk B; Lewensohn R; Viktorsson K
    Cell Death Dis; 2013 Jan; 4(1):e478. PubMed ID: 23370278
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Poly(ADP-Ribose) polymerase-1 and DNA-dependent protein kinase have equivalent roles in double strand break repair following ionizing radiation.
    Mitchell J; Smith GC; Curtin NJ
    Int J Radiat Oncol Biol Phys; 2009 Dec; 75(5):1520-7. PubMed ID: 19931734
    [TBL] [Abstract][Full Text] [Related]  

  • 67. PARP inhibition versus PARP-1 silencing: different outcomes in terms of single-strand break repair and radiation susceptibility.
    Godon C; Cordelières FP; Biard D; Giocanti N; Mégnin-Chanet F; Hall J; Favaudon V
    Nucleic Acids Res; 2008 Aug; 36(13):4454-64. PubMed ID: 18603595
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Inhibition of poly(ADP-ribose) polymerase-1 by arsenite interferes with repair of oxidative DNA damage.
    Ding W; Liu W; Cooper KL; Qin XJ; de Souza Bergo PL; Hudson LG; Liu KJ
    J Biol Chem; 2009 Mar; 284(11):6809-17. PubMed ID: 19056730
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Epigenetic basis for PARP mutagenesis in glioblastoma: A review.
    M A; Xavier J; A S F; Bisht P; Murti K; Ravichandiran V; Kumar N
    Eur J Pharmacol; 2023 Jan; 938():175424. PubMed ID: 36442619
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Poly (ADP) ribose polymerase inhibition: A potential treatment of malignant peripheral nerve sheath tumor.
    Kivlin CM; Watson KL; Al Sannaa GA; Belousov R; Ingram DR; Huang KL; May CD; Bolshakov S; Landers SM; Kalam AA; Slopis JM; McCutcheon IE; Pollock RE; Lev D; Lazar AJ; Torres KE
    Cancer Biol Ther; 2016; 17(2):129-38. PubMed ID: 26650448
    [TBL] [Abstract][Full Text] [Related]  

  • 71. TNKS1BP1 functions in DNA double-strand break repair though facilitating DNA-PKcs autophosphorylation dependent on PARP-1.
    Zou LH; Shang ZF; Tan W; Liu XD; Xu QZ; Song M; Wang Y; Guan H; Zhang SM; Yu L; Zhong CG; Zhou PK
    Oncotarget; 2015 Mar; 6(9):7011-22. PubMed ID: 25749521
    [TBL] [Abstract][Full Text] [Related]  

  • 72. PARP-1-Targeted Radiotherapy in Mouse Models of Glioblastoma.
    Jannetti SA; Carlucci G; Carney B; Kossatz S; Shenker L; Carter LM; Salinas B; Brand C; Sadique A; Donabedian PL; Cunanan KM; Gönen M; Ponomarev V; Zeglis BM; Souweidane MM; Lewis JS; Weber WA; Humm JL; Reiner T
    J Nucl Med; 2018 Aug; 59(8):1225-1233. PubMed ID: 29572254
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Targeting PBK/TOPK decreases growth and survival of glioma initiating cells in vitro and attenuates tumor growth in vivo.
    Joel M; Mughal AA; Grieg Z; Murrell W; Palmero S; Mikkelsen B; Fjerdingstad HB; Sandberg CJ; Behnan J; Glover JC; Langmoen IA; Stangeland B
    Mol Cancer; 2015 Jun; 14():121. PubMed ID: 26081429
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Poly (ADP-ribose) polymerase inhibitors selectively induce cytotoxicity in TCF3-HLF-positive leukemic cells.
    Piao J; Takai S; Kamiya T; Inukai T; Sugita K; Ohyashiki K; Delia D; Masutani M; Mizutani S; Takagi M
    Cancer Lett; 2017 Feb; 386():131-140. PubMed ID: 27894958
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Structure and function of poly(ADP-ribose) polymerase-1: role in oxidative stress-related pathologies.
    Virág L
    Curr Vasc Pharmacol; 2005 Jul; 3(3):209-14. PubMed ID: 16026317
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Poly (ADP-ribose) polymerase (PARP) inhibition in cancer: Potential impact in cancer stem cells and therapeutic implications.
    Rizvi A; Merlin MA; Shah GM
    Eur J Pharmacol; 2021 Nov; 911():174546. PubMed ID: 34600907
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Radiation-induced synthetic lethality: combination of poly(ADP-ribose) polymerase and RAD51 inhibitors to sensitize cells to proton irradiation.
    Wéra AC; Lobbens A; Stoyanov M; Lucas S; Michiels C
    Cell Cycle; 2019 Aug; 18(15):1770-1783. PubMed ID: 31238782
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Resurrection of PARP Inhibitors in Breast Cancer.
    Lyons TG; Robson ME
    J Natl Compr Canc Netw; 2018 Sep; 16(9):1150-1156. PubMed ID: 30181424
    [TBL] [Abstract][Full Text] [Related]  

  • 79. The toxicity of nitrofuran compounds on melanoma and neuroblastoma cells is enhanced by Olaparib and ameliorated by melanin pigment.
    McNeil EM; Ritchie AM; Melton DW
    DNA Repair (Amst); 2013 Nov; 12(11):1000-6. PubMed ID: 24070777
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Activation of Wnt signaling promotes olaparib resistant ovarian cancer.
    Yamamoto TM; McMellen A; Watson ZL; Aguilera J; Ferguson R; Nurmemmedov E; Thakar T; Moldovan GL; Kim H; Cittelly DM; Joglar AM; Brennecke EP; Wilson H; Behbakht K; Sikora MJ; Bitler BG
    Mol Carcinog; 2019 Oct; 58(10):1770-1782. PubMed ID: 31219654
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.